Financials data is unavailable for this security.
View more
Year on year Cytosorbents Corp grew revenues 4.79% from 34.69m to 36.35m while net income improved from a loss of 32.81m to a smaller loss of 28.51m.
Gross margin | 64.56% |
---|---|
Net profit margin | -68.70% |
Operating margin | -67.37% |
Return on assets | -48.23% |
---|---|
Return on equity | -125.05% |
Return on investment | -59.94% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Cytosorbents Corp fell by 8.22m. Cash Flow from Financing totalled 14.47m or 39.82% of revenues. In addition the company used 21.66m for operations while cash used for investing totalled 936.24k.
Cash flow per share | -0.4798 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.3082 |
---|---|
Tangible book value per share | 0.3082 |
More ▼
Balance sheet in USDView more
Current ratio | 2.12 |
---|---|
Quick ratio | 1.71 |
Total debt/total equity | 0.817 |
---|---|
Total debt/total capital | 0.4496 |
More ▼